Riskpilot← Back to searchSign inGet full accessTORHEIM PHARMACEUTICALS AS
ASActiveOrg 997185374Rødtvetkroken 8G, 0956 OsloResearch and experimental development on social sciences and humanities · NACE 7220Est. 20110 employeestorheim.no
Revenue 2024
NOK 0
EBITDA margin
—
-244% vs 2023
Equity ratio
102.3%
Financial strength
Net profit 2024
NOK -16K
-378% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -17K | -244% |
| Net profit | NOK -16K | -378% |
| Total assets | NOK 126K | -13% |
| Equity | NOK 129K | -11% |
| Employees | 0 | — |
Legal name
TORHEIM PHARMACEUTICALS AS
Org number
997185374
Legal form
Aksjeselskap
NACE code
7220 · Research and experimental development on social sciences and humanities
Founded
3. august 2011
Share capital
NOK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Bistå i utviklingen av fremtidsrettede løsninger for helsevesenet og andre samfunnsbærende sektorer gjennom forskning, utvikling og innovasjon. Bidra til å løse utfordringer knyttet til miljø, pasientsikkerhet og dyrevelferd.
Address
Rødtvetkroken 8G, 0956 Oslo
Website
torheim.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 341 | 1 073 | 0 | 305 | 246 | 465 | 502 | 465 | 233 | 299 | 163 | 0 | 0 | 0 |
| Staff expenses | −239 | −358 | −34 | −869 | −25 | 86 | −500 | −313 | −32 | −28 | −2 | −0 | −0 | −0 |
| EBITDA | 38 | 601 | −128 | −780 | 11 | 432 | −90 | 69 | 116 | 207 | 151 | −5 | −5 | −17 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 38 | 601 | −128 | −780 | 11 | 432 | −90 | 69 | 116 | 207 | 151 | −5 | −5 | −17 |
| Net financials | 1 | 12 | 16 | 17 | 1 | 1 | 0 | 0 | 1 | −370 | 70 | 8 | 2 | 1 |
| Profit before tax | 39 | 613 | −112 | −763 | 12 | 433 | −89 | 69 | 117 | −163 | 221 | 3 | −3 | −16 |
| Tax | 8 | 172 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 31 | 441 | −112 | −763 | 12 | 433 | −89 | 69 | 117 | −163 | 221 | 3 | −3 | −16 |
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 449 | 818 | 489 | 197 | 429 | 382 | 444 | 548 | 648 | 375 | 216 | 218 | 145 | 126 |
| Equity | 131 | 572 | 460 | −303 | −291 | 142 | 53 | 122 | 239 | 77 | 96 | 148 | 144 | 129 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 318 | 246 | 28 | 500 | 720 | 239 | 391 | 426 | 410 | 298 | 120 | 70 | 1 | −3 |
| Total debt | 318 | 246 | 28 | 500 | 720 | 239 | 391 | 426 | 410 | 298 | 120 | 70 | 1 | −3 |
EBITDA margin
-1674800.0%
This company
15.8%
Market median
-10600100% vs market
20112024
Equity ratio
102.3%
This company
38.2%
Market median
+168% vs market
20112024
Return on equity
-12.1%
This company
18.4%
Market median
-166% vs market
20112024
Net profit margin
-1561400.0%
This company
8.1%
Market median
-19276643% vs market
20112024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20112024
Debt / equity
-0.02×
This company
0.62×
Market median
+103% vs market
20112024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ÅJ Deputy Member | Deputy Member | 2011 | — | — |
EA Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TORHEIM PHARMACEUTICALS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Åge Jostein Torheim | Deputy Member | 0 companies |
| Eirik Albert Torheim | Chief Executive Officer | 0 companies |